Red Light Therapy: a Potential Strategy to Reduce Sports Injury Risk?
Condition(s) studied
Investigational drug(s) / intervention(s)
Near-infrared photobiomodulation: Exposure to a near-infrared LED panel emitting wavelengths range of 800-860 nm for 10 minutes at a distance of 15 cm and 100% intensity. Mobility and flexibility tests (KWT and AKET) are performed immediately before and after the exposure.
Cycling Warm-up: 10 minutes cycling warm-up on a stationary cycle ergometer at 55-75% of maximum heart rate, followed by mobility and flexibility assessments.
Study summary
This study investigates whether near-infrared light therapy can acutely improve ankle dorsiflexion mobility and hamstring flexibility, two factors associated with sports injury risk. Healthy adult students will complete three randomized conditions: a control session, a 10-minute cycling warm-up, and a 10-minute exposure to a red and near-infrared LED panel (MITO LIGHT®). Mobility and flexibility will be assessed before and after each condition using the Knee-to-Wall Test (KWT) and the Active Knee Extension Test (AKET). The study aims to determine whether photobiomodulation may serve as a potential strategy to reduce musculoskeletal injury risk.
Eligibility
Primary outcome measure(s)
- Ankle dorsiflexion range of motion — Immediately before and immediately after each condition (control, cycling warm-up, and near-infrared photobiomodulation)
Ankle dorsiflexion range of motion will be assessed using the weight-bearing lunge test (knee-to-wall test). The distance from the hallux to the wall (cm) will be measured with the knee touching the wall and the heel on the floor. Higher values indicate greater dorsiflexion mobility
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Human Movement Laboratory, Escola Superior de Saúde da Universidade de Aveiro (ESSUA) | Aveiro | Aveiro District |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07477678 on ClinicalTrials.gov ↗ ← All trials in Portugal